Carolyn J. Anderson | Washington University in St. Louis, Department of Chemistry

Home » Faculty	Low-Bandwidth Page \| Directory \| Search \| Contact
Carolyn J. Anderson

	Professor Biological Chemistry, Inorganic Chemistry, Nuclear Chemistry School of Medicine, Division of Radiological Sciences Department of Chemistry Washington University in St. Louis St. Louis, MO 63130-4899 Phone: (314)362-8427 andersoncj@wustl.edu	Research Group
Undergraduate: University of Wisconsin Superior, Superior, WI-B.S.-1985-Chemistry Graduate: Florida State University, Tallahassee, FL-Ph.D.-1990-Inorganic Chemistry 1990-1992 Research Associate, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO
Research The major focus of our research is the development, evaluation and application of radiopharmaceuticals containing metal radionuclides for diagnostic imaging and targeted radiotherapy of cancer. We are particularly interested in ⁶⁴Cu (T1/2 = 12.7 hours), in large part because it emits β+ particles for positron emission tomography (PET) imaging and β- particles for radiotherapy. The agents we are studying are ⁶⁴Cu-labeled bifunctional chelate-receptor ligand conjugates for imaging and therapy of various types of cancer. Somatostatin is a peptide hormone of which certain tumors have upregulated receptors. We are developing new radiolabeled bifunctional-chelator-peptide conjugates of these receptor ligands for PET and radiotherapy. We are also interested in understanding the in vivo metabolism and in vitro subcellular metabolism of these agents. One aspect of these metabolism studies is the correlation of the nature of the bifunctional chelate and the radiometal to differences in the biodistribution of radiometal-chelate-biomolecule conjugates. With collaborators from the University of New Hampshire, we developed cross-bridged macrocyclic chelators for ⁶⁴Cu that form highly stable complexes in animal models in vivo. The greater in vivo stability of ⁶⁴Cu-labeled cross-bridged chelator somatostatin conjugates impart signficantly improved uptake in tumors with more rapid clearance from blood and liver compared to ⁶⁴Cu-labeled somatostatin analogs with less stable chelators. Another major area of research in our lab is the development of imaging agents targeting the process of cancer metastasis. Towards this goal we are investigating radiolabeled inhibitors of matrix metalloproteinases and radiolabeled integrin ligands for imaging of tumors to predict metastatic potential and radiolabeled integrin ligands for targeting bone metastases.
Selected Publications Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des, 2007; 13:3-16. Sprague JE, Kitaura H, Zou W, Ye Y, Achilefu S, Weilbaecher KN, Teitelbaum SL, Anderson CJ. Non-invasive Imaging of Osteoclasts in Parathyroid Hormone-Induced Osteolysis Using a ⁶⁴Cu-labeled RGD Peptide. J Nucl Med, 2007; 48: 311-318. Sprague JE, Peng Y, Fiamengo AL, Woodin KS, Southwick EA, Weisman GR, Wong EH, Golen JA, Rheingold AL, Anderson CJ. Synthesis, Characterization and in vivo Studies of Cu(II)-64-labeled Cross-bridged Tetraazamacrocycle-amide Complexes as Models of Peptide Conjugate Imaging Agents. J. Med Chem, 2007; 50:2527-2535. Eiblmaier M, Meyer LA, Anderson CJ. The Role of p53 in the Trafficking of Copper-64 to Tumor Cell Nuclei. Cancer Biol Ther, 2008; 7:63-69.

Page Last Updated: August 11th, 2008